AstraZeneca to use Classification System in global discovery R&D.
Jan 31, 2003
Pharmaceutical firm to use Classification System in global discovery R&D.
Reel Two Inc. today announced it has licensed to AstraZeneca its Classification System text and data mining application. AstraZeneca Global Research and Development will be using the system as part of its extensive bioinformatics effort.
Reel Two is an advanced data mining software firm offering text and non-text analysis and classification applications for the life sciences industry. The Reel Two Classification System uses patent-pending technology to rapidly analyze large volumes of information and categorize unstructured data. This process shows users clear links between documents and concepts, or predicts future behavior and patterns from analytical data.
Life science applications include linking classification of published and internal research according to client-specified categories or standard vocabularies, such as the Gene Ontology. Reel Two's Classification System is also being used for such tasks as gene sequence and disease data analysis.
Reel Two's products are fast, easy to use, quick to adapt to client's data requirements and easily customizable for end users. These were essential criteria for AstraZeneca in its evaluations of classification software. "AstraZeneca has a well-founded reputation for adopting cutting-edge technologies to leverage the power of its scientific resources, said Reel Two Senior Vice-President Nicko Goncharoff. Reel Two is pleased to be a part of AstraZeneca's impressive commitment to R&D."
The Reel Two Classification System builds its predictive models in real-time, enabling users to monitor and alter performance on the fly, enormously speeding the process of building taxonomies and classifying data in a production environment. An interactive graphical user interface, results ranking and performance analysis tools give users completely transparent access to the classification process. Less time and effort for training the system means even complex classification solutions can be up and running in a matter of minutes or hours, rather than days or weeks.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $16.4 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. For more information, please visit http://www.astrazeneca.com/.